BRIEF published on 12/09/2024 at 06:35, 1 year 9 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 1 year 9 months ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 9 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year 10 months ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
BRIEF published on 12/05/2024 at 13:00, 1 year 10 months ago Formycon rejoint le SDAX de la Bourse allemande Stratégie De Marché SDAX Formycon Biosimilaires Bourse Allemande
PRESS RELEASE published on 12/05/2024 at 12:55, 1 year 10 months ago Formycon joins the SDAX of the German Stock Exchange Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
BRIEF published on 11/28/2024 at 06:35, 1 year 10 months ago Formycon Reports Continued Growth in 2024 Nine-Month Results Financial Results Market Position FDA Approval Biosimilars Strategic Growth
BRIEF published on 11/28/2024 at 06:35, 1 year 10 months ago Formycon annonce une croissance continue de ses résultats sur neuf mois en 2024 Résultats Financiers Croissance Stratégique Approbation De La FDA Biosimilaires Positionnement Sur Le Marché
PRESS RELEASE published on 11/28/2024 at 06:30, 1 year 10 months ago Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes Formycon reports nine-month results for 2024 with operational successes and growth trajectory, including product approvals and new biosimilar candidates Biosimilars Growth Trajectory Formycon Nine-month Results Operational Successes
BRIEF published on 11/19/2024 at 06:35, 1 year 10 months ago Formycon Announces Earnings Call and Conference Participation Financial Results Investor Conference Frankfurt Stock Exchange Formycon AG Earnings Call
Published on 10/05/2026 at 22:30, 8 hours 10 minutes ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 15 hours 55 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 16 hours 10 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 16 hours 10 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 16 hours 40 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/06/2026 at 03:00, 3 hours 40 minutes ago Qupital Unveils World’s First AI-Driven On-Chain E-Commerce Lending Protocol, Accelerating Web3 Global Trade Finance
Published on 10/05/2026 at 22:25, 8 hours 15 minutes ago LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 8 hours 35 minutes ago AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 9 hours 30 minutes ago Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 9 hours 34 minutes ago EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 22:12, 8 hours 28 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 8 hours 28 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 12 hours 27 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 12 hours 27 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 12 hours 40 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
